WallStSmart

Enterprise Products Partners LP (EPD)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enterprise Products Partners LP generates 338% more annual revenue ($52.60B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 11.1%. EPD appears more attractively valued with a PEG of 2.16. VRTX earns a higher WallStSmart Score of 66/100 (B-).

EPD

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 6.5Value: 7.3Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EPDSignificantly Overvalued (-40.0%)

Margin of Safety

-40.0%

Fair Value

$25.32

Current Price

$38.99

$13.67 premium

UndervaluedFair: $25.32Overvalued
VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EPD3 strengths · Avg: 8.3/10
Market CapQuality
$81.20B9/10

Large-cap with strong market position

P/E RatioValuation
14.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

EPD4 concerns · Avg: 3.0/10
PEG RatioValuation
2.164/10

Expensive relative to growth rate

EPS GrowthGrowth
1.7%4/10

1.7% earnings growth

Revenue GrowthGrowth
-2.9%2/10

Revenue declined 2.9%

Free Cash FlowQuality
$02/10

Negative free cash flow — burning cash

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EPD

The strongest argument for EPD centers on Market Cap, P/E Ratio, Price/Book.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : EPD

The primary concerns for EPD are PEG Ratio, EPS Growth, Revenue Growth.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

EPD profiles as a declining stock while VRTX is a mature play — different risk/reward profiles.

EPD carries more volatility with a beta of 0.57 — expect wider price swings.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

Monitor OIL & GAS MIDSTREAM industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VRTX scores higher overall (66/100 vs 50/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enterprise Products Partners LP

ENERGY · OIL & GAS MIDSTREAM · USA

Enterprise Products Partners LP provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGL), crude oil, petrochemicals, and refined products. The company is headquartered in Houston, Texas.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?